Hvordan påvirkes lægers adfærd, opfattelser og holdninger?

Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med. 1982;73:4-8.
Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med 1988;26:1183-9.
Orlowski JP and Wateska L. The effects of pharmaceutical firm enticements on physician prescribing patterns. Chest. 1992; 102:270-273.
Chren MM, Landefeld CS. Physicians’ behavior and their interaction with drug companies. JAMA. 1994;271:684-689.
Caudill, TS, Johnson, MS, Rich EC, McKinney, WP. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch of Fam Med. 1996;5:201-206.
Chew, LD, et al. A Physician Survey of the Effect of Drug Sample Availability on Physicians’ Behavior. J Gen Int Med. 2000;15: 478-483.
Wazana A.Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA. 2000 Jan 19;283(3):373-80.
Watkins C, Moore L, Harvey I, Carthy P, Robinson E, Brawn R. Characteristics of general practitioners who frequently see drug industry representatives: national cross sectional survey. BMJ 2003;326: 1178-9
Rogers WA, Mansfield PR, Braunack-Mayer AJ, Jureidini JN. The ethics of pharmaceutical industry relationships with medical students. Med J Aust. 2004;180(8):411-4.
Norris P, Herxheimer A, Lexchin J, Mansfield P. Drug Promotion: What We Know What We Have Yet to Learn. World Health Organisation and
Health Action International. Geneva: 2005.
Sierles FS, Brodkey AC, Cleary LM, McCurdy FA, Mintz M, Frank J, Lynn DJ, Chao J, Morgenstern BZ, Shore W, Woodard JL. Medical students’ exposure to and attitudes about drug company interactions: a national survey. JAMA. 2005 Sep 7;294(9):1034-42.
Andersen M, Kragstrup J, Søndergaard J. How conducting a clinical trial affects physicians’ guideline adherence and drug preferences. JAMA. 2006 Jun 21;295(23):2759-64.
Steinman MA, Bero LA, Chren MM, Landefeld CS. Narrative review: the promotion of gabapentin: an analysis of internal industry documents. Ann Intern Med. 2006 Aug 15;145(4):284-93.
Kumar CJ, Deoker A, Kumar A, et al. Awareness and attitudes about disease mongering among medical and pharmaceutical students PLoS Medicine(2006) 3(4) e213.
Chimonas S, Brennan TA, Rothman DJ. Physicians and drug representatives: exploring the dynamics of the relationship. J Gen Intern Med. 2007 Feb;22(2):184-90.
Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Ann Intern Med. 2008 Aug 19;149(4):251-8
Applbaum K. Getting to yes: corporate power and the creation of a psychopharmaceutical blockbuster. Cult Med Psychiatry. 2009 Jun;33(2):185-215
Spurling G, Mansfield P. General practitioners and pharmaceutical sales representatives: quality improvement research. Qual Saf Health Care. 2007 Aug;16(4):266-70.
Gagnon MA, Lexchin J: The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine/Public Library of Science 2008, 5(1):3
Anderson BL, Silverman GK, Loewenstein GF, Zinberg S, Schulkin J. Factors associated with physicians’ reliance on pharmaceutical sales representatives. Acad Med. 2009 Aug;84(8):994-1002.
Fugh-Berman AJ, Scialli AR, Bell AM. Why lunch matters: assessing physicians’ perceptions about industry relationships. J Contin Educ Health Prof. 2010 Summer;30(3):197-204.
Chimonas S, Rozario NM, Rothman DJ. Show Us the Money: Lessons in Transparency from State Pharmaceutical Marketing Disclosure Laws. Health Serv Res. 2010 February; 45(1): 98–114.
Spurling GK, Mansfield PR, Montgomery BD, Lexchin J, Doust J, Othman N, Vitry AI. Information from Pharmaceutical Companies and the Quality, Quantity, and Cost of Physicians’ Prescribing: A Systematic Review. PLoS Med 2010 Oct 19; 7:(10):
Campbell EG, Rao SR, DesRoches CM, Iezzoni LI, Vogeli C, Bolcic-Jankovic D, Miralles PD. Physician professionalism and changes in physician-industry relationships from 2004 to 2009. Arch Intern Med. 2010 Nov 8;170(20):1820-6. Erratum in: Arch Intern Med. 2010 Dec 13;170(22):1966.
Fugh-Berman A, Brown SR, Trippett R, Bell AM, Clark P, Fleg A, Siwek J. Closing the door on pharma? A national survey of family medicine residencies regarding industry interactions. Acad Med. 2011 May;86(5):649-54.
Mitchell J, Read J. Attention-deficit hyperactivity disorder, drug companies and the internet. Clin Child Psychol Psychiatry. 2012 Jan;17(1):121-39.
Robertson, C., Rose, S. and Kesselheim, A. S. Effect of Financial Relationships on the Behaviors of Health Care Professionals: A Review of the Evidence. The Journal of Law, Medicine & Ethics 2012;40: 452–466.
Saver, R. S. Is It Really All about the Money? Reconsidering Non-Financial Interests in Medical Research. The Journal of Law, Medicine & Ethics 2012;40: 467–481.
Sah, S. Conflicts of Interest and Your Physician: Psychological Processes That Cause Unexpected Changes in Behavior. The Journal of Law, Medicine & Ethics 2012;40: 482–487.
Mintzes B, Lexchin J, Sutherland JM, Beaulieu MD, Wilkes MS, Durrieu G, Reynolds E. Pharmaceutical Sales Representatives and Patient Safety: A Comparative Prospective Study of Information Quality in Canada, France and the United States.J Gen Intern Med. 2013 Apr 5. [Epub ahead of print]
Rasmussen K, Schroll J, Gøtzsche PC, Lundh A. Under-reporting of conflicts of interest among trialists: a cross-sectional study, J R Soc Med. 2014 Nov 11. [Epub ahead of print]